Provenance Wealth Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Provenance Wealth Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-16	Closed	-$2.11K	–	554
2025 Q1	$2.11K	Hold	16	–	–	﹤0.01%	401
2024 Q4	$1.34K	Hold	16	–	–	﹤0.01%	468
2024 Q3	$1.17K	Hold	16	–	–	﹤0.01%	515
2024 Q2	$1.1K	Hold	16	–	–	﹤0.01%	436
2024 Q1	$1.11K	Hold	16	–	–	﹤0.01%	467
2023 Q4	$1.15K	Sell	16 -1	-6%	-$58	﹤0.01%	516
2023 Q3	$886	Buy	+17	New	+$990	﹤0.01%	422

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Provenance Wealth Advisors's ITCI Position: Q2 2025 in Review

Provenance Wealth Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 16 shares — an estimated $2.11K sold.

Provenance Wealth Advisors first reported a position in ITCI in Q3 2023 and held it in 7 quarters. The position peaked at $2.11K in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Provenance Wealth Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Provenance Wealth Advisors sold 16 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $2.11K.
Provenance Wealth Advisors first reported a position in Intra-Cellular Therapies Inc. in Q3 2023 and held it in 7 quarters.
Provenance Wealth Advisors's Intra-Cellular Therapies Inc. position peaked at $2.11K in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Provenance Wealth Advisors's 13F filing for Q2 2025, filed 15 Aug 2025.